Literature DB >> 2732474

A new simplified procedure for C1 inhibitor purification. A novel use for jacalin-agarose.

Y Pilatte1, C H Hammer, M M Frank, L F Fries.   

Abstract

C1 inhibitor (C1-INH), the major regulatory protein of the classical pathway of complement activation, is also involved in the regulation of several other plasma proteolytic systems including the coagulation, fibrinolytic and contact systems. All the previously published methods for the purification of C1-INH are time-consuming and some do not yield highly pure protein. Recently, it was reported that Jack fruit (Artocarpus integrifolia) lectin, also called jacalin, binds C1-INH. Since jacalin binds only a small number of human serum proteins it appeared that jacalin-agarose affinity chromatography would constitute a very selective early step for the purification of C1-INH. Consequently we have designed a new, simplified three-step procedure for the purification of C1-INH which includes PEG fractionation, jacalin-agarose chromatography and hydrophobic interaction chromatography on phenyl-Sepharose which takes advantage of the marked hydrophilicity of the inhibitor. This procedure has three major advantages over those which have been the most frequently used. Firstly, it includes only two fast chromatographic steps. Secondly, because the C1-INH pool is cleanly and predictably separated from the unwanted proteins by differential elution conditions in both chromatographic steps, no antigenic or functional assays are required to define the desired peaks. Thirdly, only the final product is dialyzed while all other methods required several buffer changes. For these reasons this procedure is much faster and simpler than the previously published methods. About 10-12 mg of highly purified and fully active C1-INH can be obtained within 1 day from 120 ml of plasma giving an average yield of 40-45%. This method may thus be highly adaptable to bulk purification for clinical use or for preparation of genetically or pathologically altered C1-INH from clinical specimens.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2732474     DOI: 10.1016/0022-1759(89)90286-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  10 in total

1.  Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site.

Authors:  R B Parad; J Kramer; R C Strunk; F S Rosen; A E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  Chymotrypsin inhibitory activity of normal C1-inhibitor and a P1 Arg to His mutant: evidence for the presence of overlapping reactive centers.

Authors:  K S Aulak; A E Davis; V H Donaldson; R A Harrison
Journal:  Protein Sci       Date:  1993-05       Impact factor: 6.725

3.  Lectin affinity chromatography.

Authors:  I West; O Goldring
Journal:  Mol Biotechnol       Date:  1994-10       Impact factor: 2.695

4.  Endothelial targeting with C1-inhibitor reduces complement activation in vitro and during ex vivo reperfusion of pig liver.

Authors:  L Bergamaschini; G Gobbo; S Gatti; L Caccamo; P Prato; M Maggioni; P Braidotti; R Di Stefano; L R Fassati
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

5.  Metabolic alteration of the N-glycan structure of a protein from patients with a heterozygous protein deficiency.

Authors:  Fuming Zhang; Andrew D Bries; Sybil C Lang; Qun Wang; David W Murhammer; John M Weiler; Robert J Linhardt
Journal:  Biochim Biophys Acta       Date:  2004-12-24

6.  Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance.

Authors:  Haining Yu; Eva M Muñoz; R Erik Edens; Robert J Linhardt
Journal:  Biochim Biophys Acta       Date:  2005-08-15

7.  Mechanism of action of anti-C1-inhibitor autoantibodies: prevention of the formation of stable C1s-C1-inh complexes.

Authors:  S He; R B Sim; K Whaley
Journal:  Mol Med       Date:  1998-02       Impact factor: 6.354

8.  Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.

Authors:  E Eldering; C C Huijbregts; J H Nuijens; A J Verhoeven; C E Hack
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

9.  Complement 1 inhibitor is a regulator of the alternative complement pathway.

Authors:  H Jiang; E Wagner; H Zhang; M M Frank
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

10.  Simultaneous activation of complement and coagulation by MBL-associated serine protease 2.

Authors:  Anders Krarup; Russell Wallis; Julia S Presanis; Péter Gál; Robert B Sim
Journal:  PLoS One       Date:  2007-07-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.